From discovery to clinical evidence. Understand what a result establishes, and what remains uncertain.
A virtual counterpart makes an irresistible promise: explore possibilities before acting. Its usefulness depends on what it knows, what it leaves out, and how it earns trust.
4 min read
FDA’s 2026 terminology change, a historical liver-chip benchmark and a transparent error-cost model show what a validation investment must establish.
The Elevidys safety revision informs a hypothetical surveillance budget and an eligibility-sensitive operating plan.
![CLARITY AD: 18-month CDR-SB change. Lecanemab: 1.21; Placebo: 1.66. CDR-SB points. Reported trial values [1]; greater increase indicates greater worsening.](/images/consulting/external-controls-neurology-evidence-reserve-record.svg)
Leqembi’s randomized evidence and AMT-130’s September update frame a client’s sensitivity analysis and evidence reserve.
![Original tissue-agnostic evidence: one bounded response estimate. Objective response: 39.6. Response (%). 149 patients across five trials [1]; not a required ADC response threshold.](/images/consulting/adc-phase-two-response-filing-runway-record.svg)
A September 2026 ADC filing withdrawal becomes a hypothetical evidence-gap, delay and cash-runway assignment.
A drug–diagnostic operating model turns assay availability, testing attrition and turnaround into measurable launch dependencies.
![IRIS: major cytogenetic response at 18 months. Imatinib: 87.1; Comparator: 34.7. Response (%). Historical randomized trial [1]; not survival or a forecast.](/images/consulting/imatinib-target-validation-capital-gate-record.svg)
IRIS and a recent biomarker-led approval frame a hypothetical oncology program’s recruitment, assay and capital decisions.
AI can widen the search for a medicine. The more interesting question is how scientists decide which possibilities deserve to become experiments.
4 min read
Sotatercept and OCEANIC-AF illustrate why a benefit claim must remain tied to its population, comparator and endpoint.
Why a small, well-defined population still needs rigorous comparison, diagnostic execution and a clear financing plan.
Positive and negative trial examples show why endpoint choice, patient selection and execution costs must be assessed together.
Historical industry data support careful study of biomarker-led programs while leaving important causal and operational questions open.
An oncology cohort shows why regulatory status and demonstrated patient benefit need separate tracking.
A defined FDA approval cohort can reveal the shape of innovation. It cannot rank clinical value or predict the next development program.
A result can move in the right direction while a person’s daily life remains difficult. Patient-reported outcomes help research ask more precisely what improvement means.
4 min read
The 2006 first-in-human event makes safety accountability an operating requirement.
An EGFR-selected trial demonstrates why population definition belongs in the clinical and access model.
APOLLO joined a molecular mechanism to 18-month clinical measures in a defined hereditary disease.
A 2020 trial shows why recovery time, mortality, and hospital economics require separate interpretations.
A fictional day asks what earlier detection, personalized treatment, and connected care would need to deliver for a real person.
5 min read